Kinsella T J
Department of Human Oncology, University of Wisconsin Medical School, Madison, Wisconsin 53792, USA.
Cancer J Sci Am. 1996 Jul-Aug;2(4):184-93.
The use of biochemical modifiers of nucleotidc metabolism as clinical radiosensitizers holds renewed interest in the oncology community in light of the recently reported positive clinical trials cited in this article. In general, this approach to radiosensitization attempts to limit the effect of tumor repopulation and to reduce the efficiency of radiation damage repair in tumors during treatment. Since these drug-radiation interactions lack tumor specificity, further improvements in the therapeutic gain can only result by identifying exploitable differecnces in the biologic properties of tumors and dose-limiting normal tissues. The rapid evolution of our understanding of differences in cell cycle regulation in rumors and normal tissues is clearly one area that will likely provide new strategies for these combined modality approaches.
鉴于本文中引用的近期报道的阳性临床试验结果，使用核苷酸代谢的生化修饰剂作为临床放射增敏剂在肿瘤学界重新引起了关注。一般来说，这种放射增敏方法试图限制肿瘤再增殖的影响，并降低治疗期间肿瘤中辐射损伤修复的效率。由于这些药物与辐射的相互作用缺乏肿瘤特异性，只有通过识别肿瘤和剂量限制正常组织生物学特性中可利用的差异，才能进一步提高治疗增益。我们对肿瘤和正常组织细胞周期调控差异理解的迅速发展显然是一个可能为这些联合治疗方法提供新策略的领域。
